世界中医药

作者	单位
林海¹，王静怡²，王晓燕¹，王开娜¹，刘岗¹，吕富荣¹，杨琳¹，查鹏洲¹	1 西安市中医医院，西安市西华门2号，710003； 2 陕西省中医医院

摘要点击次数: 1103

全文下载次数: 1401

中文摘要:

目的：观察养心开郁片治疗中-轻度抑郁症的临床疗效及安全性。方法：将135例患者随机分为治疗组90例，对照组45例，治疗组口服养心开郁片4片/次，3次/d；对照组口服氟西汀25mg/d，上午服用；夜间睡前30min 2组均给予枣安胶囊2～4粒。于第一次就诊及用药第2和6周末分别以HAMD-17、中医症状量表、SCL-90、SDS、SAS、SERS量表及实验室检查评估疗效与安全性。结果:用药前2组各类量表评分无统计学差异(P>0.05)；用药2周后治疗组各类评分均有所改善（P<0.05）；6周后治疗组总有效率85.55%，各类评分较用药前有显著差异（P<0.05）。2组间总有效率、各类量表的各时间点评分基本无统计学差异；SAS评分治疗组优于对照组（P<0.05）。治疗组中医症状少寐多梦、心烦心悸改善明显，对照组忧伤郁闷改善明显（P<0.05）。SERS评估、安全性评估均未发现明显不良反应。结论:提示养心开郁片治疗中轻度抑郁症具有较好的疗效，2周即可起效，治疗6周后效果明显，与氟西汀相当，安全性良好。

English Summary:

To observe efficacy and safety of Yangxin Kaiyu tablets on moderate or mild depression. Method: 135 patients were randomized to the tablet arm (n=90, 4 tablets, 3 times per day) and Fluoxetine arm (n=45, 25mg/day in the morning); background medication: 4 Zaoan capsules 30min before bed. Efficacy and safety parameters include the Hamilton depression rating scale (HAMD-17), TCM syndrom scale, Symptom Checklist 90 (SCL-90), self-rating scale for depression (SDS), self-rating scale for Anxiety (SAS), Rating Scale for Side Effects(SERS) and related laboratory analysis at WEEK2 and WEEK6. Results:There were no statistical significance of before treatment (P>0.05). At WEEK2 both groups improved on all parameters (P<0.05); At WEEK6 total effective rate for the tablet was 85.55%. The total effective rate and the scores of various rating scale at the set time points were not statistically different between the two groups. The SAS assessment was better with the tablet. Palpitation, insomnia and the symptom of depression improved significantly in the treatment group and the control group respectively (P<0.05). No safety concerns revealed during the study. Conclusion: the Yangxin Kaiyu tablets can treat moderate or mild depression without obvious safety issue.

查看全文查看/发表评论下载PDF阅读器